

001437749-25-003833astc20241231 10q.htm 001001907ASTROTECH Corp false--06-30q220250.00110012,500,0002,500,000280,898280,898280,8980.0011001250,000,000250,000,0001,712,0451,712,0451,701,7291,701,72910,31610,31631http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNethttp://www.astrotechcorp.com/20241231#OperatingAndFinanceLeasesLiabilityCurrenthttp://www.astrotechcorp.com/20241231#OperatingAndFinanceLeasesLiabilityCurrent07-012024-12-31xbrli:shares00010019072025-02-12thunderdome:itemis04217:USD00010019072024-12-3100010019072024-06-30iso4217:USDxbrli:shares00010019072024-10-012024-12-3100010019072023-10-012023-12-3100010019072023-07-012023-12-310001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2024-06-300001001907astc:CommonStockOutstandingMember2024-06-300001001907us-gaap:TreasuryStockCommonMember2024-06-300001001907us-gaap:AdditionalPaidInCapitalMember2024-06-300001001907us-gaap:RetainedEarningsMember2024-06-300001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2024-07-012024-09-300001001907astc:CommonStockOutstandingMember2024-07-012024-09-300001001907us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001001907us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001001907us-gaap:RetainedEarningsMember2024-07-012024-09-300001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-3000010019072024-07-012024-09-300001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2024-09-300001001907astc:CommonStockOutstandingMember2024-09-300001001907us-gaap:TreasuryStockCommonMember2024-09-300001001907us-gaap:AdditionalPaidInCapitalMember2024-09-300001001907us-gaap:RetainedEarningsMember2024-09-300001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-3100010019072024-10-012024-12-310001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2024-10-012024-12-310001001907astc:CommonStockOutstandingMember2024-10-012024-12-310001001907us-gaap:TreasuryStockCommonMember2024-10-012024-12-310001001907us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310001001907us-gaap:RetainedEarningsMember2024-10-012024-12-310001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-310001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2024-12-310001001907astc:CommonStockOutstandingMember2024-12-310001001907us-gaap:TreasuryStockCommonMember2024-12-310001001907us-gaap:AdditionalPaidInCapitalMember2024-12-310001001907us-gaap:RetainedEarningsMember2024-12-310001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-06-300001001907astc:CommonStockOutstandingMember2023-06-300001001907us-gaap:TreasuryStockCommonMember2023-06-300001001907us-gaap:AdditionalPaidInCapitalMember2023-06-300001001907us-gaap:RetainedEarningsMember2023-06-300001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000010019072023-06-300001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-07-012023-09-300001001907astc:CommonStockOutstandingMember2023-07-012023-09-300001001907us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001001907us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001001907us-gaap:RetainedEarningsMember2023-07-012023-09-300001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-3000010019072023-07-012023-09-300001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-10-012023-12-310001001907astc:CommonStockOutstandingMember2023-10-012023-12-310001001907us-gaap:TreasuryStockCommonMember2023-10-012023-12-310001001907us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310001001907us-gaap:RetainedEarningsMember2023-10-012023-12-310001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-310001001907us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-12-310001001907astc:CommonStockOutstandingMember2023-12-310001001907us-gaap:TreasuryStockCommonMember2023-12-310001001907us-gaap:AdditionalPaidInCapitalMember2023-12-310001001907us-gaap:RetainedEarningsMember2023-12-310001001907us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100010019072023-12-310001001907astc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907astc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907astc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907astc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907astc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-30utr:sgft0001001907astc:ResearchAndDevelopmentFacilityMemberastc:AustinTexasMember2021-04-27utr:M0001001907astc:ResearchAndDevelopmentFacilityMemberastc:AustinTexasMember2022-11-22utr:M0001001907astc:ResearchAndDevelopmentFacilityMemberastc:AustinTexasMember2022-12-01utr:Yxbrli:pure0001001907astc:FurnitureFixturesEquipmentAndLeaseholdImprovementsMember2024-12-310001001907astc:FurnitureFixturesEquipmentAndLeaseholdImprovementsMember2024-06-300001001907us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-12-310001001907us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-12-310001001907us-gaap:ConstructionInProgressMember2024-06-300001001907astc:RightsPlanMember2022-12-3100010019072023-07-012024-06-300001001907us-gaap:RestrictedStockMember2024-10-012024-12-310001001907us-gaap:EmployeeStockOptionMember2024-10-012024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-12-310001001907us-gaap:ShortTermInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-300001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-300001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-300001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-300001001907us-gaap:ShortTermInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-300001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-300001001907us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOffFairValueFairValueDisclosureMemberastc:CorporateGovernmentDebtETFsSecuritiesMember2024-06-300001001907us-gaap:ShortTermInvestments

[illegible]

[illegible]

[illegible]

BreathTech™’s license for the AMS Technology and collection of data through a clinical study. Amendments to the CCF JDA extended the expiration date to April 30, 2025. Á In conjunction with the CCF JDA, BreathTech entered into an Investigator-Initiated Study Agreement with The Cleveland Clinic Foundation (á€œCCF IISAA€), effective March 31, 2021, to expand the application of breath analysis by collecting and studying the gaseous portion of exhaled breath for markers of lung and systemic diseases. The pilot study concluded and the CCF IISA terminated in accordance with its terms on February 7, 2025.Á We believe additional studies will be required to continue exploration of technologies which may provide non-invasive methods of monitoring and studying lung and systemic diseases.Á 21 Table of Contents Á While the CCF JDA remains active, we believe the work to commercialize this application of the AMS Technology will require many years and significant investment due to regulatory requirements and have determined to deploy capital instead to our other subsidiaries. We are also exploring how the advancements and knowledge derived from our research on the BreathTech use case can be applied in our other existing and potential new business units. Á Pro-Control, Inc.Á Á €ˆ On December 12, 2023, we announced the formation of our new wholly owned subsidiary, Pro-Control, and ATIA€’s entry into an exclusive license with Pro-Control to utilize our AMS Technology for industrial process control applications involving chemical distillation outside of the agriculture industry. Pro-Control uses advanced mass spectrometer instrumentation to monitor and control the production and operations of manufacturing processes using real-time, in-process samples. Pro-Control provides the vital spectral qualitative and quantitative data needed to control the production parameters (temperatures, flow, speed, and pressure) while significantly improving efficiency.Á Á €ˆ Pro-Controlá€ has introduced its proprietary Pro-Control Maximum Value Processingá€ and the Pro-Control 1000-D2á,€ mass spectrometer, which in combination are designed to test, measure and increase reaction intermediates, purity and percent yields in industrial processes.á€ Á Á Critical Accounting Estimates Á The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States Generally Accepted Accounting Principles (á€œU.S. GAAPá€). The preparation of these financial statements requires us to make estimates and judgments that directly affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities in the Companyá€’s consolidated financial statements and accompanying notes. A critical accounting estimate is one that involves a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management continuously evaluates its critical accounting policies and estimates, including those used in evaluating the recoverability of long-lived assets, recognition of revenue, valuation of inventory, and the recognition and measurement of loss contingencies, if any. Actual results may differ from these estimates under different assumptions or conditions.Á Á We believe that the following accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements. Á Results of Operations Á Three months ended December 31, 2024, compared to three months ended December 31, 2023: Á Selected consolidated financial data for the quarters ended December 31, 2024, andÁ 2023Á is as follows: Á Á Three Months Ended December 31, Á (In thousands) Á 2024 Á Á 2023 Á Revenue Á \$ 261 Á Á \$ 1,115 Á Cost of revenue Á \$ 106 Á Á \$ 583 Á Gross profit Á \$ 155 Á Á \$ 532 Á Gross margin Á 59 % Á Á 48 % Operating expenses: Á Á Á Á Á Á Selling, general and administrative Á \$ 2,039 Á Á \$ 2,022 Á Research and development Á \$ 2,437 Á Á \$ 1,578 Á Total operating expenses Á \$ 4,476 Á Á \$ 3,600 Á Loss from operations Á (4,321) Á Á (3,068) Á Other income and expense, net Á Á \$ 312 Á Á \$ 427 Á Net loss Á \$ (4,009) Á Á \$ (2,641) Á 22 Table of Contents Á Revenue á€ˆ Total revenue decreased by \$854 thousandÁ during the second quarter of fiscal yearÁ 2025, compared to the second quarter of fiscal yearÁ 2024. Iná the second quarter of fiscal yearÁ 2025 revenue wasá€ related to sales of our TRACER 1000, a government grant andá ongoing consumableá€ and recurring maintenance services of the TRACER 1000. In the second quarter of fiscal year 2024, revenue was related to the sales of our TRACER 1000 along with ongoing consumable and recurring maintenance services of the TRACER 1000.á€ The decrease in revenue is the result of selling fewerÁ devices during the secondÁ quarter of fiscal year 2025 thanÁ sold in the second quarter of fiscal year 2024. Á Cost of Revenue á€ˆÁ Gross profit is comprised of revenue less cost of revenue. Our costs of revenue include materials, overhead, warranty expenses,Á shipping, and labor. Cost of revenue decreased by \$477á€ thousand during the secondÁ quarter of fiscal yeará€ 2025, compared to the secondÁ quarter of fiscal yeará€ 2024,á€ because of the decrease in device sales. Gross margin increased by 11%á€ in the secondÁ quarter of fiscal yeará€ 2025, compared to the secondÁ quarter of fiscal yeará€ 2024. Theá device sales in fiscal year 2025 had a higher margin compared to the device sales in fiscal year 2024Á which resulted in an increase in gross margin.Á In addition, grant revenue had a minimalÁ cost of revenue and lower costs of revenueÁ due to a sales mix.Á These factors resulted in an increase in gross margin. Á Operating Expenses á€ˆ Operating expenses increased \$876 thousand, or 24.3%, during the second quarter of fiscal yearÁ 2025, compared to the second quarter of fiscal yearÁ 2024. Significant changes to operating expenses include the following: Á Á — Selling, general and administrative expenses remained consistentÁ during the second quarter of fiscal yearÁ 2025, compared to the second quarter of fiscal yearÁ 2024. Á Á — Research and development expenses increased \$859 thousand, or 54.4%, during the second quarter of fiscal yearÁ 2025, compared to the second quarter of fiscal yearÁ 2024.Á largely driven by increased spending onÁ contractors and employeesÁ to support the development of our mass spectrometry offering and expenses related to cross-platform improvements to our technology. Á Other IncomeÁ and Expense, net á€ˆÁ Other income and expense, net decreased \$115Á thousandÁ during the secondÁ quarter of fiscal yearÁ 2025,Á compared to the secondÁ quarter of fiscal yearÁ 2024, due to less investments earning interest income. Á Six months ended December 31, 2024, compared to six months ended December 31, 2023: Á Selected consolidated financial data for the six months ended December 31, 2024, andÁ 2023Á is as follows: Á Á Six Months Ended December 31, Á (In thousands) Á 2024 Á Á 2023 Á Revenue Á \$ 295 Á Á \$ 1,540 Á Cost of revenue Á \$ 131 Á Á \$ 825 Á Gross profit Á \$ 164 Á Á \$ 715 Á Gross margin Á 56 % Á Á 46 % Operating expenses: Á Á Á Á Á Á Selling, general and administrative Á \$ 3,727 Á Á \$ 3,668 Á Research and development Á \$ 4,386 Á Á \$ 4,350 Á Total operating expenses Á \$ 8,113 Á Á \$ 7,118 Á Loss from operations Á (7,949) Á Á (6,403) Á Other income and expense, net Á Á \$ 662 Á Á \$ 850 Á Net loss Á \$ (7,287) Á Á \$ (5,553) Á Á Revenue á€ˆ Total revenue decreased by \$1.2Á millionÁ during theá six months ended December 31, 2024, compared to the six months ended December 31, 2023. In theá six months ended December 31, 2024, revenue wasá€ related to sales of our TRACER 1000, a government grant andá ongoing consumableá€ and recurring maintenance services of the TRACER 1000. In the six months ended December 31, 2023, revenue was related to the sales of our TRACER 1000 along with ongoing consumable and recurring maintenance services of the TRACER 1000.á€ The decrease in revenue is the result of selling fewer devices duringÁ fiscal year 2025 compared to fiscal year 2024. Á 23 Table of Contents Á Cost of Revenue á€ˆÁ Gross profit is comprised of revenue less cost of revenue. Our costs of revenue include materials, overhead, warranty expenses,Á shipping, and labor. Cost of revenue decreased by \$694á€ thousand duringÁ six months ended December 31, 2024, compared to the six months ended December 31, 2023,á€ because of the decrease in device sales. Gross margin increased by 10%á€ in the duringÁ six months ended December 31, 2024, compared to the six months ended December 31, 2023.Á Theá device sales in fiscal year 2025 had a higher margin compared to the device sales in fiscal year 2024.Á In addition,Á grant revenue had a minimalÁ cost of revenue and lower costs of revenue due to a sales mix.Á These factors resulted in an increase in gross margin. Á Operating Expenses á€ˆ Operating expenses increased \$1 million, or 14.0%, during the six months ended December 31, 2024, compared to the six months ended December 31, 2023. Significant changes to operating expenses include the following: Á Á — Selling, general and administrative expenses remained consistentÁ during the six months ended December 31, 2024, compared to theá six months ended December 31, 2023. Á Á — Research and development expenses increased \$936Á thousand, or 27.1%, during the six months ended December 31, 2024, compared to the six months ended December 31, 2023.Á largely driven by increases in contractors personnel count to support the development of our mass spectrometry offering and expenses related to cross-platform improvements to our technology. Á Other IncomeÁ and Expense, net á€ˆÁ Other income and expense, net decreased \$188Á thousandÁ during the six months ended December 31, 2024,Á compared to the six months ended December 31, 2023, due to less investments earning interest income. Á Liquidity and Capital Resources Á Cash Flows Á The following is a summary of the change in our cash and cash equivalents: Á Á Á Six Months Ended December 31, Á (In thousands) Á 2024 Á Á 2023 Á Á Change Á Change in cash and cash equivalents: Á Á Á Á Á Á Net cash used in operating activities Á \$ (6,730) Á Á \$ (4,850) Á Á \$ (1,880) Á Net cash used in investing activities Á Á \$ (472) Á Á \$ 1,828 Á Á \$ (2,300) Á Net cash used in financing activities Á Á \$ (79) Á Á \$ (90) Á Á \$ 11 Á Net change in cash and cash equivalents Á \$ (7,281) Á Á \$ (3,112) Á Á \$ (4,169) Á Cash and Cash Equivalents Á As of December 31, 2024, we held cash and cash equivalents of \$3.2 million, and our working capital was approximately \$25.5 million. As of June 30, 2024, we had cash and cash equivalents of \$10.4 million, and our working capital was approximately \$32.2 million. Cash and cash equivalents decreased \$7.2Á millionÁ as of December 31, 2024, compared to June 30, 2024, due to funding our continuing operating expenses. Á Operating Activities Á Cash used in operating activities increasedÁ \$1.9 millionÁ for the six months ended December 31, 2024, compared to the six months ended December 31, 2023, due toÁ increased use of cash to fund operating losses and working capital. Á Investing Activities Á Cash used in investing activities increasedÁ \$2.3 millionÁ for the six months ended December 31, 2024, compared to the six months ended December 31, 2023, due primarily to not selling short-term time depositÁ investments. Á Financing Activities Á Cash used in financing activities was slightly lowerÁ for the six months ended December 31, 2024, compared to the six months ended December 31, 2023.Á Á We did not have any material off-balance sheet arrangements as of December 31, 2024. Á 24 Table of Contents Á Liquidity Á There have been no material updates to our expectations for our short- and long-term liquidity and operating capital requirements since our Annual Report on Form 10-K for the year ended June 30, 2024. Á Á Income Taxes Á Provision for Income Tax Á The Companyá€’s effective tax rate is 0% for income tax for the six months ended December 31, 2024, and the Company expects that its effective tax rate for the full fiscal year 2025Á will be 0%. Á Based on the weight of available evidence, including net cumulative losses and expected future losses, the Company has determined that it is more likely than not that its U.S. federal and state deferred tax assets will not be realized and therefore a full valuation allowance has been provided on the U.S. federal and state net deferred tax assets. Á In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change net operating loss (NOL) Á carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code. Generally, U.S. state laws have laws similar to Internal Revenue Code Section 382. The annual limitation generally is determined by multiplying the value of the Companyá€’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforward before utilization. Á The Company files U.S. federal and state income tax returns.Á The Company is not currently subject to any income tax examinations. The Company has net operating loss carryovers dating back to the June 2002 year, which generally allows all tax years to remain open to income tax examinations for all years for which there are loss carryforwards. Á Uncertain Tax Positions Á The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. The Company currently has approximately \$593 thousand of uncertain tax positions as of December 31, 2024, all of which are accounted as contra-deferred tax assets. The Company does not expect any significant changes to its uncertain tax positions in the coming 12 months. Á Income Taxes Á There is a \$1 thousand provision for state minimum tax expense during the six months ended December 31, 2023.Á Á Á ITEM 3.Á QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Á Not applicable to smaller reporting companies. Á 25 Table of Contents Á ITEM 4.Á CONTROLS AND PROCEDURES Á Disclosure Controls and Procedures Á We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SECá€’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management was required to apply its judgment in evaluating and implementing possible controls and procedures. Management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer have concluded that the Companyá€’s disclosure controls and procedures were effective as ofÁ December 31, 2024, at the reasonable assurance level. Á Changes in Internal Controls over Financial Reporting Á There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter ended December 31, 2024, that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. Á 26 Table of Contents Á PART II: OTHER INFORMATION Á ITEM 1.Á LEGAL PROCEEDINGS Á From time to time, the Company is subject to legal and administrative proceedings, settlements, investigations, claims and actions. The Companyá€’s assessment of the likely outcome of litigation matters is based on its judgment of a number of factors including experience with similar matters, past history, precedents, relevant financial and other evidence and facts specific to the matter. Notwithstanding the uncertainty as to the final outcome, based upon the information currently available, management does not believe any matters, individually or in aggregate, will have a material adverse effect on the Companyá€’s financial position or results of operations. Á ITEM 1A. RISK FACTORS Á Our business, financial condition, results of operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth in our Form 10-K and our Form 10-Qs, the occurrence of any one of which could have a material adverse effect on our actual results. Á Except as set forth below, thereÁ haveÁ beenÁ noÁ materialÁ changesÁ toÁ the risk factors and other cautionary statements described under the heading á€œItem 1A Risk Factorsá€ included in our Form 10-K for the fiscal year ended June 30, 2024. Á Our manufacturing operations are dependent upon third party suppliers, including single source suppliers, making us vulnerable to external factors such as trade restrictions, supply shortages and price fluctuations, which could harm our business. Á We are subject to the risks inherent in the manufacturing of our products, including industrial accidents, environmental events, strikes and other labor disputes, capacity constraints, as well as tariffs and other trade restrictions, global shortages, disruptions in supply chain and loss or impairment of key suppliers, as well as natural disasters and other external factors over which we have no control. Our products contain several critical components, including certain electrical components such as specialized cables and specialized pumps. Some of the suppliers of critical components or materials are single source suppliers. Although we believe there are suitable alternative suppliers for these components, the replacement of existing suppliers or the identification and qualification of suitable second sources may require significant time, effort and expense, and could result in delays in production, which could negatively impact our business operations and revenue. We do not have supply agreements with certain suppliers of these critical components and materials beyond purchase orders and, although we maintain a safety stock inventory for certain critical components, forecasted amounts may be inaccurate and we may experience shortages as a result of serious supply problems with these suppliers. Additionally, the U.S. has recently enacted and proposed to enact significant new tariffs on certain goods or countries, and may have new or retaliatory tariffs imposed on the U.S., which could increase the cost of raw materials and components we purchase. There can be no assurance that our supply of components will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In addition, loss of any critical component provided by a single source supplier could require us to change the design of our manufacturing process based on the functions, limitations, features and specifications of the replacement components. Á In addition, several other non-critical components and materials that comprise our products are currently manufactured by a single supplier or a limited number of suppliers. In certain of these cases, we have not yet qualified alternate suppliers. A supply interruption or an increase in demand beyond our current suppliersá€ capabilities could harm our ability to manufacture our products unless and until new sources of supply are identified and qualified. Our reliance on these suppliers subjects us to a number of risks that could harm our business, including: Á Á Á — interruption of supply resulting from modifications to or discontinuation of a supplierá€’s operations; Á Á Á Á Á — trade disputes or other political conditions or economic conditions; Á Á Á Á Á — delays in the manufacturing operations of our suppliers, or in the delivery of parts and components to support such manufacturing operations, due to the impact of public health issues, epidemics or pandemics, such as COVID-19; Á Á Á Á Á — delays in product shipments resulting from uncorrected defects, reliability issues, or a supplierá€’s variation in a component; Á Á Á Á Á — a lack of long-term supply arrangements for key components with our suppliers; Á Á Á Á Á — inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms; Á Á Á Á Á — difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner; Á Á Á Á Á — a modification or change in a manufacturing process or part that unknowingly or unintentionally negatively impacts the operation of our platform; Á Á Á Á Á — production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications; Á Á Á Á Á — delay in delivery due to our

suppliers prioritizing other customer orders over ours; Â Â Â Â Â— damage to our brand reputation caused by defective components produced by our suppliers; Â Â Â Â Â— increased cost of our warranty program due to product repair or replacement based upon defects in components produced by our suppliers; and Â Â Â Â Â— fluctuation in delivery by our suppliers due to changes in demand from us or their other customers. Â Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could result in increased costs and impair our ability to meet the demand of our customers, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. 27 Table of Contents Â Changes in U.S. trade policy, including changes to existing trade agreements and any resulting changes in international trade relations, may have a material adverse effect on us. Â The recent change in the U.S.â€™s approach to international trade may impact existing bilateral or multi-lateral trade agreements and treaties with foreign countries. The U.S. has imposed tariffs on certain foreign goods and may increase tariffs or impose new ones, and certain foreign governments have retaliated and may continue to do so. We derive a significant portion of our revenues from international sales, which makes us especially vulnerable to increased tariffs. Additionally, the implementation of these or other tariffs may lead to increased costs for our product components, which could impact our ability to maintain competitive pricing in the market. Changes in U.S. trade policy have created ongoing turmoil in international trade relations, and it is unclear what future actions the U.S. government or foreign governments will or will not take with respect to tariffs or other international trade agreements and policies. Current trade negotiations may fail, which may exacerbate these risks. Ongoing or new trade wars or other governmental action related to tariffs or international trade agreements or policies could reduce demand for our products and services, increase our costs, reduce our profitability, adversely impact our supply chain or otherwise have a material adverse effect on our business and results of operations. Â ITEM 2. Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â None. Â ITEM 3. Â DEFAULTS UPON SENIOR SECURITIES Â None. Â ITEM 4. Â MINE SAFETY DISCLOSURE Â Not applicable. Â ITEM 5. Â OTHER INFORMATION Â None. Â 28 Table of Contents Â Â ITEM 6.Â EXHIBITS Â Exhibit No. Â Description Â Incorporation by Reference Â Â Â Â 3.1 Â Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware. Â Exhibit 3.1 to Form 8-K filed on December 28, 2017. Â Â Â Â 3.2 Â Amended and RestatedÂ Bylaws of the RegistrantÂ (incorporated by reference to Exhibit 3.1 of the Registrantâ€™s Form 8-K filed with the Securities and Exchange Commission on August 1, 2023). Â Exhibit 3.1A to Form 8-K filed on August 1, 2023. Â Â Â Â 3.3 Â Certificate of Designations of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware. Â Exhibit 3.3 to Form 8-K filed on December 28, 2017. Â Â Â Â 3.4 Â Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Preferred Stock, as filed with the Delaware Secretary of State on April 17, 2019. Â Exhibit 3.2 to Form 8-K filed on April 23, 2019. Â Â Â Â 3.5 Â Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation. Â Exhibit 3.1 to Form 8-K filed on July 1, 2020. Â Â Â Â 3.6 Â Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation. Â Exhibit 3.1 to Form 8-K filed on October 12, 2021. Â Â Â Â 3.7 Â Third Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation. Â Exhibit 3.1 to Form 8-K filed on November 23, 2022. Â Â Â Â 4.1 Â Rights Agreement between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, dated as of December 21, 2022. Â Exhibit 4.1 to Form 8-K filed on December 21, 2022. Â Â Â Â 4.2 Â Amendment No. 1 to Rights Agreement dated as of December 18, 2023, to the Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent, dated as of December 21, 2022. Â Exhibit 4.2 to Form 8-K filed on December 18, 2023. Â Â Â Â 4.3 Â Amendment No. 2 to Rights Agreement dated as of December 12, 2024, to the Rights Agreement between the Company and Equiniti Trust Company, as Rights Agent, dated as of December 21, 2022. Â Exhibit 4.3\* to Form 8-K filed on December 12, 2024. Â Â Â Â 10.1A Â Independent Contractor Agreement by and between the Company and Jaime Hinojosa, dated January 21, 2025. Â Exhibit 10.1 to Form 8-K filed on January 24, 2025. Â Â Â Â 10.2A Â Independent Contractor AgreementÂ by and between the Company and Ryan Polk, dated January 22, 2025. Â Exhibit 10.3 to Form 8-K filed on January 24, 2025. Â Â Â Â 10.3A Â Form of Amended and Restated Indemnification Agreement. Â Exhibit 10.1 to Form 8-K filed on December 19, 2024. Â 29 Table of Contents Â Exhibit No. Â Description Â Incorporation by Reference Â Â Â Â 31.1 Â Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934. Â Filed herewith. Â Â Â Â 31.2 Â Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934. Â Filed herewith. Â Â Â Â 32.1 Â Certification pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934. Â Furnished herewith. Â Â Â Â 101.INS Â Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. Â Filed herewith. Â Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema Document Â Filed herewith. Â Â Â Â 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Filed herewith. Â Â Â Â 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document Â Filed herewith. Â Â Â Â 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document Â Filed herewith. Â Â Â Â 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Filed herewith. Â Â Â Â 104 Â The cover page from the Companyâ€™s Quarterly Report on Form 10-Q for the quarter ended December 31, 2024, has been formatted in Inline XBRL. Â Â Â Â Â Management contract or compensatory plan arrangement Â Â 30 Table of Contents Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â Astrotech Corporation Â Â Date:Â February 14, 2025 Â /s/ Ryan Polk Â Ryan Polk Â Chief Financial Officer, Treasurer and SecretaryÂ (Principal Financial and Accounting Officer) Â 31 0001437749-25-003833ex 749958.htm Exhibit 31.1A Certification of Chief Executive OfficerSection 302 CertificationÂ I, Thomas B. Pickens III, certify that:Â 1. I have reviewed this quarterly report on Form 10-Q of Astrotech Corporation; Â 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this quarterly report; and Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: February 14, 2025 /s/ Thomas B. Pickens III Â Thomas B. Pickens III Â Chief Executive Officer, Chief Technology Officer,Â and Chairman of the Board (Principal ExecutiveÂ Officer) Â Â Â Â 0001437749-25-003833ex 749959.htm Exhibit 31.2A Â Certification of Chief Financial OfficerSection 302 CertificationÂ I, Ryan Polk, certify that:Â 1. I have reviewed this quarterly report on Form 10-Q of Astrotech Corporation; Â 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this quarterly report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: February 14, 2025 /s/ Ryan Polk Â Ryan Polk Â Chief Financial Officer, Treasurer and SecretaryÂ (Principal Financial and Accounting Officer) Â Â 0001437749-25-003833ex 749960.htm Exhibit 32.1A Certification Pursuant to 18 U.S.C. Section 1350,as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Â Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Thomas B. Pickens III, the Chief Executive Officer, and Jaime Hinojosa, the Chief Financial Officer, of Astrotech Corporation (the “Company”), hereby certify, that, to their knowledge:Â 1. The Quarterly Report on Form 10-Q for the period ended December 31, 2024 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: February 14, 2025 Â Â Â /s/ Thomas B. Pickens III Â Thomas B. Pickens III Â Chief Executive Officer, Chief Technology Officer, and Chairman of the Board (Principal ExecutiveÂ Officer) Â Â Â Â /s/ Ryan Polk Â Ryan Polk Â Chief Financial Officer, Treasurer and SecretaryÂ (Principal Financial and Accounting Officer) Â Â